B
Bergenbio ASA
OSE:BGBIO
Bergenbio ASA
OSE:BGBIO
Price:
0.491
NOK
2.29%
Market Cap:
kr19.2m
Relative Value
The Relative Value of one BGBIO stock under the Base Case scenario is 1.604 NOK. Compared to the current market price of 0.491 NOK, Bergenbio ASA is Undervalued by 69%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BGBIO
Relative Value
Base Case
1.604
NOK
Undervaluation 69%
B
Multiples Across Competitors
BGBIO Competitors Multiples
Bergenbio ASA Competitors
Bergenbio ASA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| NO |
B
|
Bergenbio ASA
OSE:BGBIO
|
19.2m NOK | 3.6 | -0.2 | 0.4 | 0.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
383.2B USD | 6.4 | 163.2 | 15.9 | 22.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.2B USD | 5.5 | 28.2 | 19.9 | 19.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
181.9B USD | 6.2 | 22.4 | 15.2 | 15.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.9B USD | 10.2 | 32.7 | 24 | 25.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.7B USD | 5.7 | 18.1 | 15.4 | 17.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
87.9B AUD | 3.9 | 20.4 | 13.6 | 17 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.6B EUR | 14.4 | 33.8 | 57.7 | 59.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
